Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
Subscribe To Our Newsletter & Stay Updated
